Bleeding Due to Warfarin Treatment: Five Years of Experience
Yıl: 2019 Cilt: 31 Sayı: 3 Sayfa Aralığı: 125 - 134 Metin Dili: İngilizce DOI: 10.5336/cardiosci.2019-65895 İndeks Tarihi: 28-04-2020
Bleeding Due to Warfarin Treatment: Five Years of Experience
Öz: Objective: The aim of the study was to determine the factors contributing to the development of bleeding and mortality in patients admitted to emergency department with any nontraumaticbleeding (major or minor) complaint while under warfarin therapy. Material and Methods: Patients whoadmitted to the emergency department of a university hospital between 2009 and 2013 due to bleedingcomplications during warfarin treatment were included in the study which was conducted in a prospective and observational design. The demographic characteristics of the patients, the reasons for using warfarin, the types and localizations of the bleedings, the treatments applied, the duration of hospitalizationand mortality data were recorded. The factors that are likely to be effective on bleeding and mortality(age, hemodynamic status on admission, initial INR levels, warfarin dose, etc.) were analyzed comparatively. SPSS version 16.0 program was used for statistical analysis and p<0.05 was considered statisticallysignificant. Results: A total of 518 patients were enrolled in the study. The mean age of the patients was64.19±13.28 years, 229 (44.2%) of the patients were male. More than half of the patients were over 65years of age, the most common indication for warfarin was heart valve disease and atrial fibrillation, andthe most mortal bleeding type was gastrointestinal bleeding. There was no correlation between the firstINR levels on admission and the bleeding severity and mortality (p=0.577, p=0.788). The most significant indicator of mortality was hemodynamic instability during admission. Systolic and diastolic arterial blood pressure and haemoglobin levels were significantly lower (p=0.004, p=0.023, p=0.001,respectively) in nonsurvivors, whereas pulse and shock index were significantly higher (p<0.001,p<0.001). Conclusion: Patients under warfarin treatment admit to emergency services with major orminor bleeding independently from INR levels. Especially, patients aged 65 and over are at risk. Themost significant indicator of mortality appears to be hemodynamic instability during admission.
Anahtar Kelime: Konular:
Varfarin Tedavisine Bağlı Kanama: Beş Yıllık Deneyim
Öz: Amaç: Çalışmanın amacı, varfarin tedavisi altında iken (majör ya da minör) herhangi bir nontravmatik kanama şikayeti ile acil servise başvuran hastalarda, kanama gelişimi ve mortaliteye katkı sağlayan faktörleri belirlemektir. Gereç ve Yöntemler: Çalışmaya 2009-2013 yılları arasında bir üniversite hastanesi acil servisine nontravmatik kanama şikayeti ile başvuran ve varfarin kullanmakta olan hastalar dahil edildi. Çalışma prospektif, gözlemsel bir çalışma olarak yürütüldü. Hastaların demografik özellikleri, varfarin kullanma gerekçeleri, kanama tip ve lokalizasyonları, uygulanan tedaviler, yatış süreleri ve mortalite verileri kaydedildi. Kanama ve mortalite üzerine etkili olması muhtemel faktörler (yaş, başvurudaki hemodinamik durum, başlangıç INR düzeyleri, varfarin dozu vb.), karşılaştırmalı olarak analiz edildi. İstatistiksel incelemede SPSS ver. 16.0 programı kullanıldı. p <0,05 istatistiksel olarak anlamlı kabul edildi. Bulgular: Çalışmaya toplam 518 hasta alındı. Hastaların yaş ortalaması 64,19±13,28, 229’u (%44,2) erkekti. Hastaların yarısından fazlası 65 yaş üzerinde, en sık varfarin kullanım endikasyonu kalp kapak hastalığı ve atrial fibrilasyon, en fazla mortal seyreden kanama şekli gastrointestinal kanama idi. Başvuru sırasındaki ilk INR düzeyleri ile kanama ciddiyeti ve mortalite arasında bir ilişki tespit edilmemiştir (p=0,577, p=0,788). Mortal seyreden hastalarda sistolik ve diyastolik tansiyon arteryel ve hemoglobin düzeyleri anlamlı olarak (p=0,004, p=0,023, p=0,001, sırasıyla) daha düşük iken, nabız ve şok indeksi anlamlı olarak (p<0,001, p<0,001) daha yüksek bulunmuştur. Sonuç: Varfarin tedavisi altındaki hastalar, INR seviyelerinden bağımsız olarak majör ya da minör kanama şikayetleri ile acil servislere başvurmaktadırlar. Özellikle 65 yaş ve üzerindeki hastalar risk altındadırlar. Mortalitenin en anlamlı göstergesi başvuru esnasındaki hemodinamik kararsızlık olarak görünmektedir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Hambleton J. Drugs used in disorders of coaguation. In: Katzung BG, ed. Basic and Clinical Pharmacology. 9th ed. New York: A Lange Medical Book/McGraw-Hill; 2004. p.543-60.
- 2. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med. 2005;45(2):197-206. [Crossref] [PubMed]
- 3. Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BH. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004;127(1):85-9. [Crossref] [PubMed]
- 4. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol. 2002;25(10):447-54. [Crossref] [PubMed] [PMC]
- 5. Ben-Yehuda O, Redfors B. Validation of the bleeding academic research consortium bleeding definition: towards a standardized bleeding score. J Am Coll Cardiol. 2016;67(18):2145-7. [Crossref] [PubMed]
- 6. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Cardiol. 2003;41(9):1633- 52. [Crossref]
- 7. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47(4):804-8. [Crossref] [PubMed]
- 8. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631-9. [Crossref] [PubMed]
- 9. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113(1):42-51. [Crossref]
- 10. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol. 2005;96(4):595-8. [Crossref] [PubMed]
- 11. Eroğlu M, Çınar O, Çevik E, Yamanel L, Durusu M, İnal V, et al. [The analysis of cases admitted to intensive care units from emergency department due to complications related to warfarin treatment]. Turk J Emerg Med. 2011;11(1):9-12. [Crossref]
- 12. Cruickshank J, Ragg M, Eddey D. Warfarin toxicity in the emergency department: recommendations for management. Emerg Med (Fremantle). 2001;13(1):91-7. [Crossref]
- 13. Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004;164(4):1557-60. [Crossref] [PubMed]
- 14. Unverir P, Dağ T, Peynirci H, Demir E, Canbay C, Kaya A, et al. [An analysis of bleeding complications related to warfarin in the emergency department]. Turk J Emerg Med. 2006;6(3):117-21.
- 15. Nargis C, Baydın A, Karataş AD, Güven H, Doğanay Z, Yardan T. [Retrospective evaluation of patients used warfarin admitted to emergency department]. Turk J Emerg Med. 2006;6(2):56-9.
- 16. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest. 2001;119(1 Suppl): 22S-38S. [Crossref] [PubMed]
- 17. Kawai VK, Cunningham A, Vear SI, Van Driest SL, Oginni A, Xu H, et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014;15(16):1973-83. [Crossref] [PubMed] [PMC]
- 18. Weber JE, Jaggi MF, Pollack CV. Anticoagulants, antiplatelet agents and fibrinolytics. In: Tintinalli J, Kelen GD, Stabczynski JS, eds. Emergency Medicine: A Comprehensive Study Guide. 6th ed. NewYork: McGraw-Hill; 2004. p.1354-63.
- 19. Denizbaşı A, Unluer E, Güneysel Ö, Eroğlu S, KoşargelirM. [Complications of warfarin therapy and the correlation of the outcomes with INR levels]. J EmergMed. 2006;30(2):241-2. [Crossref]
- 20. Levine M, Pizon AF, Padilla-Jones A, Ruha AM. Warfarin overdose: a 25-year experience. J Med Toxicol. 2014;10(2):156-64. [Crossref] [PubMed] [PMC]
- 21. Dentali F, Ageno W, Crowther M. Treatment of coumarin associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4(9): 1853-63. [Crossref] [PubMed]
- 22. Alay M, Demir C, Atmaca M, Esen R, Dilek İ. [Evaluation of patients coming to the complication of bleeding in oral anticoagulant therapy]. Van Medical Journal. 2011;18(1):9-14.
| APA | Kocak S, ERTEKİN B, ERDEMİR ÖZTÜRK E, DÜNDAR Z, Acar T, GİRİŞGİN A, MEDNİ M (2019). Bleeding Due to Warfarin Treatment: Five Years of Experience. , 125 - 134. 10.5336/cardiosci.2019-65895 |
| Chicago | Kocak Sedat,ERTEKİN Birsen,ERDEMİR ÖZTÜRK Esma,DÜNDAR Z. Defne,Acar Tarık,GİRİŞGİN A. Sadık,MEDNİ M. Refik Bleeding Due to Warfarin Treatment: Five Years of Experience. (2019): 125 - 134. 10.5336/cardiosci.2019-65895 |
| MLA | Kocak Sedat,ERTEKİN Birsen,ERDEMİR ÖZTÜRK Esma,DÜNDAR Z. Defne,Acar Tarık,GİRİŞGİN A. Sadık,MEDNİ M. Refik Bleeding Due to Warfarin Treatment: Five Years of Experience. , 2019, ss.125 - 134. 10.5336/cardiosci.2019-65895 |
| AMA | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M Bleeding Due to Warfarin Treatment: Five Years of Experience. . 2019; 125 - 134. 10.5336/cardiosci.2019-65895 |
| Vancouver | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M Bleeding Due to Warfarin Treatment: Five Years of Experience. . 2019; 125 - 134. 10.5336/cardiosci.2019-65895 |
| IEEE | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M "Bleeding Due to Warfarin Treatment: Five Years of Experience." , ss.125 - 134, 2019. 10.5336/cardiosci.2019-65895 |
| ISNAD | Kocak, Sedat vd. "Bleeding Due to Warfarin Treatment: Five Years of Experience". (2019), 125-134. https://doi.org/10.5336/cardiosci.2019-65895 |
| APA | Kocak S, ERTEKİN B, ERDEMİR ÖZTÜRK E, DÜNDAR Z, Acar T, GİRİŞGİN A, MEDNİ M (2019). Bleeding Due to Warfarin Treatment: Five Years of Experience. Türkiye Klinikleri Cardiovascular Sciences, 31(3), 125 - 134. 10.5336/cardiosci.2019-65895 |
| Chicago | Kocak Sedat,ERTEKİN Birsen,ERDEMİR ÖZTÜRK Esma,DÜNDAR Z. Defne,Acar Tarık,GİRİŞGİN A. Sadık,MEDNİ M. Refik Bleeding Due to Warfarin Treatment: Five Years of Experience. Türkiye Klinikleri Cardiovascular Sciences 31, no.3 (2019): 125 - 134. 10.5336/cardiosci.2019-65895 |
| MLA | Kocak Sedat,ERTEKİN Birsen,ERDEMİR ÖZTÜRK Esma,DÜNDAR Z. Defne,Acar Tarık,GİRİŞGİN A. Sadık,MEDNİ M. Refik Bleeding Due to Warfarin Treatment: Five Years of Experience. Türkiye Klinikleri Cardiovascular Sciences, vol.31, no.3, 2019, ss.125 - 134. 10.5336/cardiosci.2019-65895 |
| AMA | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M Bleeding Due to Warfarin Treatment: Five Years of Experience. Türkiye Klinikleri Cardiovascular Sciences. 2019; 31(3): 125 - 134. 10.5336/cardiosci.2019-65895 |
| Vancouver | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M Bleeding Due to Warfarin Treatment: Five Years of Experience. Türkiye Klinikleri Cardiovascular Sciences. 2019; 31(3): 125 - 134. 10.5336/cardiosci.2019-65895 |
| IEEE | Kocak S,ERTEKİN B,ERDEMİR ÖZTÜRK E,DÜNDAR Z,Acar T,GİRİŞGİN A,MEDNİ M "Bleeding Due to Warfarin Treatment: Five Years of Experience." Türkiye Klinikleri Cardiovascular Sciences, 31, ss.125 - 134, 2019. 10.5336/cardiosci.2019-65895 |
| ISNAD | Kocak, Sedat vd. "Bleeding Due to Warfarin Treatment: Five Years of Experience". Türkiye Klinikleri Cardiovascular Sciences 31/3 (2019), 125-134. https://doi.org/10.5336/cardiosci.2019-65895 |
